MIT Jameel Clinic spinout Boltz launches new platform and agents, announces USD 28M seed round
CAMBRIDGE, MASSACHUSETTS – 8 JANUARY 2026 | Boltz, a project founded by Gabriele Corso, Jeremy Wohlwend and Saro Passaro at the MIT Jameel Clinic, the epicentre of artificial intelligence (AI) and health at the Massachusetts Institute of Technology (MIT), unveiled a series of major announcements today:
- the creation of a public benefit corporation,
- the release of new small-molecule and protein design agents,
- the launch of new platform Boltz Lab,
- a USD 28M seed round, and
- a partnership with Pfizer.
AI-powered molecular modelling is rapidly advancing, with the clear potential to revolutionise medicine by making biology programmable, digitising experiments and dramatically speeding up the drug development process.
The Boltz mission is to advance the frontier of AI capabilities in biology through open science and make them universally accessible to every scientist working towards a healthier, more sustainable future.
Announcements
Today, Boltz announced:
- Public benefit corporation: Boltz has incorporated a public-benefit frontier technology company to focus resources and interdisciplinary talent on creating robust products and infrastructure, beyond the scope of academia.
- Agents: To support scientists in using agentic workflows to tackle complex tasks like de-novo protein design and small-molecule hit discovery, Boltz released its first agents, which are being validated by wet lab collaborators.
- Boltz Lab: The new Boltz platform, released in beta for feedback from users, removes major adoption bottlenecks: compute cost, scalable infrastructure and intuitive, collaborative interfaces.
- Seed round: Boltz raised USD 28M in a seed round co-led by Andreessen Horowitz, Amplify Partners, Zetta Venture Partners and backed by strategic angels, including Clement Delangue (chief executive officer of Hugging Face), Factorial Capital and Obvious Ventures.
- Pfizer partnership: Through a multi-year partnership, Boltz will make Boltz Lab and its agents available to all Pfizer's scientists and will leverage Pfizer's data to create new state-of-the-art foundation models.
Boltz previously launched Boltz-1, Boltz-2 and BoltzGen, open-source models that have been used by over a hundred thousand scientists in academic and industry.
Corso, Wohlwend and Passaro are researchers at the MIT Jameel Clinic, which was co-founded in 2018 by MIT and Community Jameel.
Discover more
